An in-house CPC-based stem cell therapy using autologous adipose-derived stem cells, with the clinic director overseeing both patient care and cell quality control.

Motif Ginza Clinic's autologous adipose-derived cultured stem cell therapy is a regenerative medicine treatment provided as private medical care. Stem cells are collected from the patient's own adipose tissue, cultured in the clinic's in-house Cell Processing Center (CPC), and administered according to the treatment purpose by intravenous infusion, intra-articular injection, intradermal injection, or scalp injection.

The clinic director is personally responsible for medical consultation, patient eligibility assessment, adipose tissue collection, and cell administration. The director also makes the final decisions regarding cell culture conditions, cell quality, and whether the cultured cells are suitable for administration.

From cell collection and culture to quality control and administration, the entire process is managed within the clinic's in-house CPC. Each patient receives a cell culture certificate that includes quality testing results and other relevant information.

The clinic director has been performing autologous adipose-derived stem cell therapy since 2015 and has experience with more than 3,000 treatments, including intravenous, dermatological, and orthopedic applications.

The treatment protocol is designed to minimize the burden on patients. Cell collection requires only a very small amount of adipose tissue using a minimally invasive technique, together with approximately 10 mL of blood collection. The consultation and collection procedures are completed within approximately 40 minutes. The cells are then carefully cultured for about four weeks in the clinic's advanced cell culture facility, and freshly cultured cells are administered to the patient for treatment.

Program details

【Treatment Schedule】
Day 1
Medical consultation
Eligibility assessment
Blood tests (if required)
Adipose tissue collection

After Cell Collection
Cells are cultured in the clinic's in-house CPC for approximately 4 weeks

Approximately 4 Weeks Later
Administration according to the treatment purpose, such as:
Intravenous infusion
Intra-articular injection
Intradermal injection
Scalp injection

After Treatment
Follow-up evaluation as needed

The period from adipose tissue collection to cell administration is generally about 4 weeks.

The treatment date will be scheduled 4 weeks or later after cell collection, depending on the clinic's appointment availability.

Providing Medical Institution

Motif GINZA Clinic.

〒104-0061
4th Floor and 9th Floor, Ginza Kawai Building, 1-7-6 Ginza, Chuo-ku Tokyo

https://regenerative.motif-ginza.com/

Specialty

・Autologous adipose-derived stem cell therapy for chronic pain
・Autologous adipose-derived stem cell therapy for osteoarthritis
・Autologous adipose-derived stem cell therapy for skin aging and photoaging
・NK cell therapy for cancer treatment, cancer prevention, and improvement of immune function
・Autologous adipose-derived stem cell therapy for alopecia
・Autologous adipose-derived stem cell therapy for type 2 diabetes mellitus and prediabetes
・Autologous adipose-derived stem cell therapy for atherosclerosis
・Autologous adipose-derived stem cell therapy for menopausal disorders and decreased ovarian function

Eligibility Criteria/Exclusions for Treatment

A physician will determine whether treatment can be provided and whether the patient is eligible after reviewing the medical consultation, medical history, current medications, overall health condition, blood test results, and other relevant medical information.

The following information must be confirmed in advance:

Purpose of treatment
Target treatment area
Medical history
Current medications
Presence of infectious diseases
Use of anticoagulant medications
Possibility of pregnancy

If you plan to visit the clinic using a wheelchair, please contact the clinic in advance.

Precautions / Contraindications

Treatment may require prior evaluation or postponement depending on the presence of an infectious disease, a serious systemic medical condition, the possibility of pregnancy, the patient's medical history, current medications, or other relevant medical factors.